In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary of the virtual conference, and the pandemic, some of those earliest COVID-19 patients have still not recovered. Read More
Triple-negative breast cancer (TNBC) is among the most aggressive breast cancer subtypes, with high metastasis and recurrence rates, as well as poor survival. While various molecular targets for TNBC do exist, the low proportion of expression of these molecules in TNBC tissues limits the number of patients that benefit from molecular therapeutics. Read More
Rakovina Therapeutics Inc. has received the first synthesized batch of AI-generated ATR inhibitor compounds developed in collaboration with Variational AI Inc. The companies partnered last year to leverage the Enki generative AI platform for the development of next-generation DNA damage response (DDR) inhibitors. Read More
It was previously demonstrated that the HIV-1 integrase (IN)-interacting host factor INI1/SMARCB1 binds to HIV-1 IN through its Rpt1 domain of INI1 (INI1-Rpt1) and plays a key role in assembly and particle production. Read More
Bardet-Biedl syndrome (BBS) is a ciliopathy that leads to progressive blindness due to degeneration of cone photoreceptors, but the mechanisms behind this are not well understood. The syndrome is associated with obesity, polydactyly, cardiovascular disease and skeletal abnormalities, among others, and it is caused by genetic variants in the BBS10 gene in about 40% of the cases. Read More
Psoriasis is a chronic, recurrent and inflammatory skin disorder associated with immune system dysregulation. The abnormal immune response led to accelerated skin cell proliferation, resulting in thick plaques and chronic inflammation. The current gold-standard treatment is injectable immunosuppression. Read More
Xi’an Xintong Medicine Research Co. Ltd. has disclosed thyroid hormone receptor (THR)-β agonists reported to be useful for the treatment of atherosclerosis, hypercholesterolemia, hyperlipidemia, hepatic steatosis, thyroid cancer, diabetes, obesity and hypothyroidism. Read More
Silicosis, resulting from prolonged exposure to free crystalline silica dust, is an occupational disease characterized by silica nodules and extensive lung tissue fibrosis. The etiology of silicosis remains unclear, challenging early detection and effective treatment. Read More
To identify new genetic modifiers for epidermolysis bullosa simplex (EBS), a team led by scientists at Tel Aviv Medical Center performed exome sequencing of 195 patients with EBS from 90 different families, followed by screening for pathogenic variants in selected individuals, which resulted in identification of 3 variants in HMCN1 (codes for hemicentin-1) that co-segregated with the disease phenotype severity in 4 families. Read More
Shanghai Henlius Biologics Co. Ltd. has synthesized histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) and/or histone acetyltransferase KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of cancer. Read More
Cystic fibrosis (CF) is a life-threatening autosomal recessive disease affecting over 160,000 people worldwide. CF is caused by loss-of-function mutations in the CF transmembrane conductance regulator (CFTR) that mediates Cl and HCO3 anion transport. Read More
Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via a linker reported to be useful for the treatment of cancer, autoimmune disorders, inflammatory disorders, transplant rejection, thromboembolism, atherosclerosis, myocardial infarction and metabolic syndrome. Read More
Researchers from Life Edit Therapeutics Inc. recently reported preclinical data on the application of their gene editing technology Life Edit CRISPR system to Huntington’s disease (HD). Read More
Qingdao Putaike Biomedical Technology Co. Ltd. has described androgen receptor full length (AR-FL) and/or androgen receptor variant 7 (AR-v7) degradation inducers reported to be useful for the treatment of acne vulgaris, androgenic alopecia, cancer, hirsutism, metabolic diseases, polycystic ovary syndrome, precocious puberty and benign prostatic hyperplasia, among others. Read More
